ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Wednesday, October 29, 2025

8:00AM-8:15AM: Abstract Number: LB19

Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety, and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial

(LB19–LB24) Late-Breaking Abstracts

8:15AM-8:30AM: Abstract Number: LB20

Efficacy and Safety of Deucravacitinib up to Week 52: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs

(LB19–LB24) Late-Breaking Abstracts

8:30AM-8:45AM: Abstract Number: LB21

IDH1/2 Somatic Hotspot Mutations as Independent Drivers of Autoinflammation

(LB19–LB24) Late-Breaking Abstracts

8:45AM-9:00AM: Abstract Number: LB22

Early Evidence of Proof-of-Concept of an Albumin-DNASE1L3 Fusion Protein (NTR-441) for the Rapid Enzymatic Inactivation of NETs in SLE with DNASE1L3-Deficiency

(LB19–LB24) Late-Breaking Abstracts

9:00AM-9:15AM: Abstract Number: LB23

A Phase 1 Study of Autologous CAR-Treg Cells in Refractory Rheumatoid Arthritis: Interim Report of Safety and Efficacy

(LB19–LB24) Late-Breaking Abstracts

9:15AM-9:30AM: Abstract Number: LB24

Ianalumab demonstrates significant reduction in disease activity in patients with Sjögren’s disease: Efficacy and safety results from two global Phase 3, randomized, placebo-controlled double-blind studies (NEPTUNUS-1 and NEPTUNUS-2)

(LB19–LB24) Late-Breaking Abstracts

9:30AM-9:45AM: Abstract Number: 2645

Age-specific Incidence of Systemic Lupus Erythematosus in the United States: A Meta-Analysis of Data from the Centers for Disease Control and Prevention Lupus Registries

Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes III (2645–2650)

9:30AM-9:45AM: Abstract Number: 2651

Development and Validation of the Scleroderma Clinical Trials Consortium Classification Criteria for Systemic Sclerosis Heart Involvement

Abstracts: Systemic Sclerosis & Related Disorders – Clinical III (2651–2656)

9:30AM-9:45AM: Abstract Number: 2639

Gut Microbiome Signatures Forecast Clinical Response to Methotrexate in Treatment-Naïve Early Rheumatoid Arthritis

Abstracts: Rheumatoid Arthritis – Treatment II: Phenotyping and Personalization (2639–2644)

9:45AM-10:00AM: Abstract Number: 2652

Anti-mitochondrial antibodies in systemic sclerosis target enteric neurons and are associated with GI dysmotility

Abstracts: Systemic Sclerosis & Related Disorders – Clinical III (2651–2656)

9:45AM-10:00AM: Abstract Number: 2646

DNA methylation-based clustering reveals clinically distinct subtypes of systemic lupus erythematosus

Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes III (2645–2650)

9:45AM-10:00AM: Abstract Number: 2640

Effectiveness of Biological and Target-Synthetic Treatment in Patients with Rheumatoid Arthritis and Kidney Dysfunction: A Large Prospective Registry Study

Abstracts: Rheumatoid Arthritis – Treatment II: Phenotyping and Personalization (2639–2644)

10:00AM-10:15AM: Abstract Number: 2641

Cizutamig, a BCMA T-cell engager: preclinical to clinical translation of design optimization for the treatment of autoimmune diseases

Abstracts: Rheumatoid Arthritis – Treatment II: Phenotyping and Personalization (2639–2644)

10:00AM-10:15AM: Abstract Number: 2653

First Prospective Evaluation of Recombinant Herpes Zoster Vaccine in Systemic Sclerosis: Immunogenicity, Safety, and Disease Activity Outcomes

Abstracts: Systemic Sclerosis & Related Disorders – Clinical III (2651–2656)

10:00AM-10:15AM: Abstract Number: 2647

Unlinked Paths to SLE: Divergent Associations of DNA Methylation and Polygenic Risk Scores with SLE Features

Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes III (2645–2650)

1
2
3
…
5
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].